190 related articles for article (PubMed ID: 12544412)
1. Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.
Van Rossum AM; Gaakeer MI; Verweel S; Hartwig NG; Wolfs TF; Geelen SP; Lamberts SW; de Groot R
Pediatr Infect Dis J; 2003 Jan; 22(1):70-6. PubMed ID: 12544412
[TBL] [Abstract][Full Text] [Related]
2. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-1 and lean body mass in HIV-infected children.
Chantry CJ; Hughes MD; Alvero C; Cervia JS; Hodge J; Borum P; Moye J;
J Acquir Immune Defic Syndr; 2008 Aug; 48(4):437-43. PubMed ID: 18614924
[TBL] [Abstract][Full Text] [Related]
4. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
van Rossum AM; Bergshoeff AS; Fraaij PL; Hugen PW; Hartwig NG; Geelen SP; Wolfs TF; Weemaes CM; De Groot R; Burger DM
Pediatr Infect Dis J; 2002 Aug; 21(8):743-7. PubMed ID: 12192162
[TBL] [Abstract][Full Text] [Related]
6. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
[TBL] [Abstract][Full Text] [Related]
7. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW
Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356
[TBL] [Abstract][Full Text] [Related]
8. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
9. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children.
Miller TL; Mawn BE; Orav EJ; Wilk D; Weinberg GA; Nicchitta J; Furuta L; Cutroni R; McIntosh K; Burchett SK; Gorbach SL
Pediatrics; 2001 May; 107(5):E77. PubMed ID: 11331727
[TBL] [Abstract][Full Text] [Related]
10. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
11. Impact on weight and height with the use of HAART in HIV-infected children.
Guillén S; Ramos JT; Resino R; Bellón JM; Muñoz MA
Pediatr Infect Dis J; 2007 Apr; 26(4):334-8. PubMed ID: 17414398
[TBL] [Abstract][Full Text] [Related]
12. Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy.
Nachman SA; Lindsey JC; Pelton S; Mofenson L; McIntosh K; Wiznia A; Stanley K; Yogev R
Arch Pediatr Adolesc Med; 2002 May; 156(5):497-503. PubMed ID: 11980557
[TBL] [Abstract][Full Text] [Related]
13. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.
Saitoh A; Singh KK; Powell CA; Fenton T; Fletcher CV; Brundage R; Starr S; Spector SA
AIDS; 2005 Mar; 19(4):371-80. PubMed ID: 15750390
[TBL] [Abstract][Full Text] [Related]
14. Growth patterns in pubertal HIV-infected adolescents and their correlation with cytokines, IGF-1, IGFBP-1, and IGFBP-3.
Kessler M; Kaul A; Santos-Malavé C; Borkowsky W; Kessler J; Shah B
J Pediatr Endocrinol Metab; 2013; 26(7-8):639-44. PubMed ID: 23612635
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
[TBL] [Abstract][Full Text] [Related]
16. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.
Spector SA; Hsia K; Yong FH; Cabral S; Fenton T; Fletcher CV; McNamara J; Mofenson LM; Starr SE
J Infect Dis; 2000 Dec; 182(6):1769-73. PubMed ID: 11069252
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy.
Helle SI; Ueland T; Ekse D; Frøland SS; Holly JM; Lønning PE; Aukrust P
J Clin Endocrinol Metab; 2001 Jan; 86(1):227-33. PubMed ID: 11232005
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients.
Haugaard SB; Andersen O; Hansen BR; Orskov H; Andersen UB; Madsbad S; Iversen J; Flyvbjerg A
Metabolism; 2004 Dec; 53(12):1565-73. PubMed ID: 15562401
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 release by cultured peripheral blood mononuclear cells inversely correlates with height velocity, bone age, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 serum levels in children with perinatal HIV-1 infection.
de Martino M; Galli L; Chiarelli F; Verrotti A; Rossi ME; Bindi G; Galluzzi F; Salti R; Vierucci A
Clin Immunol; 2000 Mar; 94(3):212-8. PubMed ID: 10692240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
